{"ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement.html": {"1": ["Article 1. Definitions", {}], "2": ["Article 2. Grant of Rights", {}], "3": ["2.1 Grant of Rights to Distributor", {}], "4": ["2.2 Sub-distribution by Distributor", {}], "5": ["2.3 Supply of Product for Distributorship", {}], "6": ["2.4 No Other Rights; Other Limitations", {}], "7": ["2.5 Non-Compete Covenant", {}], "8": ["2.6 No Activities Outside the Territory or Field", {}], "9": ["3.1 Joint Steering Committee", {}], "10": ["3.2 Expenses", {}], "11": ["3.3 Alliance Managers", {}], "12": ["3.4 Scope of Governance", {}], "13": ["4.1 Nonclinical and Clinical Studies and CMC Requirements", {}], "14": ["4.2 Regulatory Activities", {}], "15": ["4.3 Distributors Right to Use and Reference", {}], "16": ["4.4 Zogenixs Right to Use and Reference", {}], "17": ["4.5 Adverse Event Reporting", {}], "18": ["4.6 Drug Safety and Pharmacovigilance System including Global Safety Database", {}], "19": ["4.7 Regulatory Audit", {}], "20": ["4.8 Use of Subcontractors", {}], "21": ["4.9 Recalls", {}], "22": ["4.1 Development Expenses", {}], "23": ["5.1 Commercialization of the Product.", {}], "24": ["5.2 Supply", {}], "25": ["5.3 Trademark Rights", {}], "26": ["5.4 Commercial Expenses", {}], "27": ["6.1 Upfront Payment", {}], "28": ["6.2 Funding to Support Development of The Product", {}], "29": ["6.3 Regulatory Milestones", {}], "30": ["6.4 Sales Milestones", {}], "31": ["6.5 Supply Payments", {}], "32": ["7.1 Payment Method", {}], "33": ["7.2 Currency Conversion", {}], "34": ["7.3 Taxes", {}], "35": ["7.4 Records", {}], "36": ["7.5 Audits", {}], "37": ["7.6 Late Payments", {}], "38": ["8.1 Confidential Information", {}], "39": ["8.2 Exceptions", {}], "40": ["8.3 Permitted Disclosures", {}], "41": ["8.4 Confidentiality of this Agreement and its Terms", {}], "42": ["8.5 Public Announcements", {}], "43": ["8.6 Publication", {}], "44": ["8.7 Prior Non-Disclosure Agreements", {}], "45": ["8.8 Equitable Relief", {}], "46": ["9.1 Ownership of Intellectual Property", {}], "47": ["9.2 Zogenix Patent Prosecution and Maintenance", {}], "48": ["9.3 Infringement by Third Parties", {}], "49": ["9.4 Third Party Intellectual Property Rights", {}], "50": ["9.5 Patent Term Restoration", {}], "51": ["9.6 Patent Marking", {}], "52": ["9.7 Zogenix Trademarks", {}], "53": ["9.8 Product Trademarks", {}], "54": ["1 0.1 Mutual Representations, Warranties and Covenants", {}], "55": ["1 0.2 Representations, Warranties and Covenants of Distributor", {}], "56": ["1 0.3 Representations and Warranties of Zogenix", {}], "57": ["1 0.4 Disclaimer", {}], "58": ["1 0.5 Limitation of Liability", {}], "59": ["1 1.1 Indemnification of Zogenix", {}], "60": ["1 1.2 Indemnification of Distributor", {}], "61": ["1 1.3 Procedure", {}], "62": ["1 1.4 Insurance", {}], "63": ["1 2.1 Term", {}], "64": ["1 2.2 Termination", {}], "65": ["1 2.3 Rights on Termination", {}], "66": ["1 2.4 Exercise of Right to Terminate", {}], "67": ["1 2.5 Damages; Relief", {}], "68": ["1 2.6 Accrued Obligations; Survival", {}], "69": ["1 3.1 Objective", {}], "70": ["1 3.2 Resolution by Executives", {}], "71": ["1 3.3 Arbitration", {}], "72": ["1 4.1 Governing Law", {}], "73": ["1 4.2 Force Majeure", {}], "74": ["1 4.3 Assignment", {}], "75": ["1 4.4 Severability", {}], "76": ["1 4.5 Notices", {}], "77": ["1 4.6 Entire Agreement; Amendments", {}], "78": ["1 4.7 Headings", {}], "79": ["1 4.8 Independent Contractors", {}], "80": ["1 4.9 Waiver", {}], "81": ["1 4.1 Cumulative Remedies", {}], "82": ["1 4.11 Waiver of Rule of Construction", {}], "83": ["1 4.12 Interpretation", {}], "84": ["1 4.13 No Third Party Beneficiaries", {}], "85": ["1 4.14 English Language", {}], "86": ["1 4.15 Counterparts", {}], "87": ["1 4.16 Further Actions", {}]}, "PerformanceSportsBrandsInc_20110909_S-1_EX-10.10_7220214_EX-10.10_Endorsement Agreement.html": {"1": ["1. Definitions", {}], "2": ["2. Term", {}], "3": ["3. Grant of License and Exclusivity", {}], "4": ["4. Retention of Rights", {}], "5": ["5. Appearances", {}], "6": ["6. Compensation", {}], "7": ["7. Supply of Endorsed Products", {}], "8": ["8. Approval of Advertising", {}], "9": ["9. Ownership", {}], "10": ["10. SAG and/or AFTRA", {}], "11": ["11. Standards", {}], "12": ["12. Events of Default", {}], "13": ["13. Termination/Remedies", {}], "14": ["14. Companys Debts", {}], "15": ["15. Indemnification", {}], "16": ["16. Insurance", {}], "17": ["17. Waiver", {}], "18": ["18. Notices", {}], "19": ["19. Assignment", {}], "20": ["20. Independent Contractor", {}], "21": ["21. Joint Venture", {}], "22": ["22. Governing Law", {}], "23": ["23 Entire Agreement", {}], "24": ["24. Amendments", {}], "25": ["25. Authority", {}], "26": ["26. Severability", {}], "27": ["27. Compliance with Laws", {}], "28": ["28. Attorneys Fees and Costs", {}], "29": ["29. Force Majeure", {}], "30": ["30. Confidentiality", {}], "31": ["31. Counterparts", {}], "32": ["Orlando, Florida 32803", {}]}, "HarpoonTherapeuticsInc_20200312_10-K_EX-10.18_12051356_EX-10.18_Development Agreement_Option Agreement.html": {"1": ["ARTICLE 1 DEFINITIONS", {}], "2": ["ARTICLE 2 COLLABORATION MANAGEMENT", {}], "3": ["ARTICLE 3 DEVELOPMENT AND REGULATORY", {}], "4": ["ARTICLE 4 COMMERCIALIZATION", {}], "5": ["ARTICLE 5 GRANT OF RIGHTS", {}], "6": ["ARTICLE 6 PAYMENTS AND RECORDS", {}], "7": ["ARTICLE 7 INTELLECTUAL PROPERTY", {}], "8": ["ARTICLE 8 PHARMACOVIGILANCE AND SAFETY", {}], "9": ["ARTICLE 9 Confidentiality AND Non-Disclosure", {}], "10": ["ARTICLE 10 REPRESENTATIONS AND Warranties", {}], "11": ["ARTICLE 11 Indemnity", {}], "12": ["ARTICLE 12 Term and Termination", {}], "13": ["ARTICLE 13 Miscellaneous", {}]}, "NUVEEN - REMARKETING AGREEMENT.html": {"1": ["Section1. Definitions", {}], "2": ["Section2. Appointment and Obligations of the Remarketing Agent", {}], "3": ["Section3. Representations, Warranties and Covenants of the Remarketing Agent and the Fund", {}], "4": ["Section4. Fees and Expenses", {}], "5": ["Section5. Resignation, Suspension and Removal of the Remarketing Agent", {}], "6": ["Section6. Dealing in the VRRM-MFP Shares", {}], "7": ["Section7. Information", {}], "8": ["Section8. Conditions to Obligations of the Remarketing Agent", {}], "9": ["Section9. Indemnification", {}], "10": ["Section10. Termination of Remarketing Agreement", {}], "11": ["Section11. Remarketing Agents Performance; Duty of Care", {}], "12": ["Section12. Amendment, Supplement or Modification of Agreements", {}], "13": ["Section13. Books and Records", {}], "14": ["Section14. Governing Law", {}], "15": ["Section15. Waiver of Jury Trial", {}], "16": ["Section16. Certain Provisions to Survive Termination of Agreement", {}], "17": ["Section17. Successors and Assigns", {}], "18": ["Section18. Headings", {}], "19": ["Section19. Severability", {}], "20": ["Section20. Counterparts", {}], "21": ["Section21. Remarketing Agent Not Acting as Underwriter", {}], "22": ["Section22. Amendment", {}], "23": ["Section23. Benefits", {}], "24": ["Section24. Notices and Wire Instructions", {}], "25": ["Section25. Liability of Officers, Trustees and Shareholders", {}], "26": ["Section26. Nonpetition Covenant", {}]}, "OTISWORLDWIDECORP_04_03_2020-EX-10.4-INTELLECTUAL PROPERTY AGREEMENT by and among UNITED TECHNOLOGIES CORPORATION, OTIS WORLDWIDE CORPORATION and CARRIER ~1.html": {"1": ["ARTICLE I DEFINITIONS", {"1": ["1.1 ['Defined Terms', '2']", {}]}], "2": ["ARTICLE II ASSIGNMENT OF SOLELY OWNED INTELLECTUAL PROPERTY RIGHTS", {"1": ["2.1 ['Assigned Intellectual Property Rights', '7']", {}]}], "3": ["ARTICLE III LICENSING OF INTELLECTUAL PROPERTY RIGHTS", {"1": ["3.1 ['Licensed Intellectual Property Rights', '8']", {}], "2": ["3.2 ['Reserved Intellectual Property Rights', '10']", {}], "3": ["3.3 ['No Rescission', '10']", {}]}], "4": ["ARTICLE IV TRADEMARKS", {"1": ["4.1 ['Ownership of United Technologies Trademarks', '10']", {}], "2": ["4.2 ['Use of United Technologies Trademarks', '11']", {}], "3": ["4.3 ['Special Trademark Provisions.', '12']", {}]}], "5": ["ARTICLE V EXCLUDED AGREEMENTS", {"1": ["5.1 ['No Change to Excluded Agreements', '12']", {}]}], "6": ["ARTICLE VI CONFIDENTIALITY", {"1": ["6.1 ['Received Information and Materials', '12']", {}], "2": ["6.2 ['Confidential Information', '12']", {}], "3": ["6.3 ['Obligations', '13']", {}], "4": ["6.4 ['Termination of UTC NDA', '13']", {}]}], "7": ["ARTICLE VII LIMITATIONS AND DISCLAIMERS", {"1": ["7.1 ['Subsequent Delivery of Intellectual Property Rights', '13']", {}], "2": ["7.2 ['No Additional Obligations', '14']", {}], "3": ["7.3 ['DISCLAIMER', '14']", {}], "4": ["7.4 ['Limitations of Liability', '14']", {}]}], "8": ["ARTICLE VIII GOVERNING LAW AND DISPUTE RESOLUTION", {"1": ["8.1 ['Governing Law', '15']", {}], "2": ["8.2 ['Alternative Dispute Resolution', '15']", {}], "3": ["8.3 ['Confidentiality', '13']", {}], "4": ["8.4 ['Equitable Relief', '13']", {}]}], "9": ["ARTICLE IX GENERAL PROVISIONS", {"1": ["9.1 ['Entire Agreement; Conflict Among Agreements', '16']", {}], "2": ["9.2 ['Assignment and Change of Control; Successor and Assigns', '16']", {}], "3": ["9.3 ['Bankruptcy', '17']", {}], "4": ["9.4 ['Amendments and Waivers', '17']", {}], "5": ["9.5 ['Notice', '18']", {}], "6": ["9.6 ['Severability', '18']", {}], "7": ["9.7 ['Counterparts', '18']", {}], "8": ["9.8 ['Further Assurances', '18']", {}], "9": ["9.9 ['Interpretation', '19']", {}]}]}, "ParatekPharmaceuticalsInc_20170505_10-KA_EX-10.29_10323872_EX-10.29_Outsourcing Agreement.html": {"1": ["Article 1 Interpretation", {"1": ["1.1 ['Definitions', '6']", {}], "2": ["1.2 ['Other Definitions', '10']", {}], "3": ["1.3 ['Currency', '10']", {}], "4": ["1.4 ['Headings', '10']", {}], "5": ["1.5 ['Exhibits', '10']", {}], "6": ["1.6 ['Applicable Law', '10']", {}]}], "2": ["Article 2 Term", {}], "3": ["2.1 Term", {"2": ["2.2 ['Effect of Expiration on Purchase Orders', '11']", {}]}], "4": ["3.1 Supply of Product", {"4": ["3.2 ['Manufacturing Services', '12']", {}], "5": ["3.3 ['Supply of Materials and Customer Material', '12']", {}], "6": ["3.4 ['Production Capacity', '14']", {}], "7": ["3.5 ['Processing Changes', '14']", {}], "8": ["3.6 ['Monitoring of Facilities', '14']", {}], "9": ["3.7 ['Subcontracting', '15']", {}]}], "5": ["3.8 [* * *]", {}], "6": ["3.9 [* * *]", {"12": ["3.1 ['Territory Expansion', '15']", {}], "13": ["3.11 ['Supply to Customer Licensees', '16']", {}], "14": ["3.12 ['Alternative Supply', '16']", {}], "15": ["4.1 ['Short Term Rolling Forecasts', '16']", {}], "16": ["4.2 ['Long Term Forecasts', '17']", {}], "17": ["5.1 ['Release Testing', '17']", {}], "18": ["5.2 ['Additional Release Testing', '18']", {}], "19": ["5.3 ['Retention Samples', '18']", {}], "20": ["5.4 ['Stability Testing', '18']", {}], "21": ["5.5 ['Reference Standards', '18']", {}], "22": ["5.6 ['Preparation of Process Qualification', '18']", {}], "23": ["6.1 ['Placement of Purchase Orders', '19']", {}], "24": ["6.2 ['Acceptance of Orders', '19']", {}], "25": ["6.3 ['Delays', '19']", {}], "26": ["6.4 ['Cancellation of Purchase Orders', '20']", {}], "27": ["6.5 ['Material Failure of Supply', '20']", {}], "28": ["6.6 ['Services', '20']", {}]}], "7": ["Article 7 Shipment of Product", {"1": ["7.1 ['Storage of Product', '20']", {}], "2": ["7.2 ['Release and Shipment of Product', '21']", {}], "3": ["7.3 ['Documentation', '21']", {}], "4": ["7.4 ['Steering Committee', '21']", {}]}], "8": ["Article 8 Acceptance of Shipments", {"1": ["8.1 ['Acceptance of Shipments', '22']", {}], "2": ["8.2 ['Dispute of Rejected Product', '22']", {}], "3": ["8.3 ['Remedies', '23']", {}]}], "9": ["Article 9 Fees", {"1": ["9.1 ['Fees', '23']", {}], "2": ["9.2 ['Adjustments to Fees', '23']", {}], "3": ["9.3 ['Taxes', '24']", {}]}], "10": ["Article 10 Invoicing and Payment", {"1": ["10.1 ['Issuance of Invoices', '24']", {}], "2": ["10.2 ['Invoice Contents', '24']", {}], "3": ["10.3 ['Delay of Shipment', '25']", {}], "4": ["10.4 ['Payment of Invoices', '25']", {}]}], "11": ["Article 11 Intellectual Property", {"1": ["11.1 ['Title', '25']", {}], "2": ["11.2 ['No Grant of Rights', '25']", {}], "3": ["11.3 ['Grant of License by Customer', '26']", {}], "4": ["11.4 ['Ownership of Inventions', '26']", {}], "5": ["11.5 ['Patents to Inventions', '26']", {}], "6": ["11.6 ['No Use of Trademarks', '26']", {}], "7": ["11.7 ['[* * *]', '26']", {}]}], "12": ["Article 12 Confidentiality & Publicity", {"1": ["12.1 ['Obligation of Confidentiality', '27']", {}], "2": ["12.2 ['Disclosure with Consent', '27']", {}], "3": ["12.3 ['Publicity', '28']", {}], "4": ["12.4 ['Disclosure Required by Law', '28']", {}], "5": ["12.5 ['Employee Confidentiality and Invention Assignment', '28']", {}], "6": ["12.6 ['Duration of Obligation', '28']", {}]}], "13": ["Article 13 Representations, Warranties and Covenants", {"1": ["13.1 ['Suppliers Representations, Warranties and Covenants', '29']", {}], "2": ["13.2 ['Customers Representations, Warranties and Covenants', '30']", {}], "3": ["13.3 ['No Other Warranty', '30']", {}], "4": ["13.4 ['No Consequential Damages and Limitation of Liability', '31']", {}]}], "14": ["Article 14 Indemnification", {"1": ["14.1 ['Indemnification of Supplier', '31']", {}], "2": ["14.2 ['Indemnification of Customer', '32']", {}], "3": ["14.3 ['[* * *]', '32']", {}], "4": ["14.4 ['Indemnification Procedure', '32']", {}]}], "15": ["Article 15 Insurance", {"1": ["15.1 ['Insurance Coverage', '32']", {}], "2": ["15.2 ['Evidence of Insurance', '33']", {}]}], "16": ["Article 16 Legal and Regulatory", {"1": ["16.1 ['Compliance with Laws', '33']", {}], "2": ["16.2 ['Maintenance of Records', '33']", {}], "3": ["16.3 ['Notice of Reports', '33']", {}], "4": ["16.4 ['Drug Master Files', '34']", {}], "5": ["16.5 ['Compliance with Regulatory Standards', '34']", {}], "6": ["16.6 ['Inspection', '34']", {}]}], "17": ["Article 17 Recalls", {"1": ["17.1 ['Safety', '34']", {}], "2": ["17.2 ['Recalls', '34']", {}], "3": ["17.3 ['Suppliers Liability for Recall', '35']", {}], "4": ["17.4 ['Customers Liability for Recall', '35']", {}], "5": ["17.5 ['Replacement Shipments', '35']", {}]}], "18": ["Article 18 Termination", {"1": ["18.1 ['Termination', '35']", {}], "2": ["18.2 ['Consequences of Termination', '36']", {}], "3": ["18.3 ['Return of Samples', '37']", {}], "4": ["18.4 ['Return of Confidential Information', '37']", {}], "5": ["18.5 ['Survival', '38']", {}]}], "19": ["Article 19 Miscellaneous", {"1": ["19.1 ['Assignment; Inurement', '38']", {}], "2": ["19.2 ['Change of Control', '39']", {}], "3": ["19.3 ['Counterparts', '39']", {}], "4": ["19.4 ['Dispute Resolution', '39']", {}], "5": ["19.5 ['Force Majeure', '39']", {}], "6": ["19.6 ['Performance', '40']", {}], "7": ["19.7 ['Further Assurances', '40']", {}], "8": ["19.8 ['Independent Contractors', '40']", {}], "9": ["19.9 ['Injunctions', '40']", {}], "10": ["19.1 ['Notices', '40']", {}], "11": ["19.11 ['Entire Agreement', '41']", {}], "12": ["19.12 ['Severability', '41']", {}], "13": ["19.13 ['Waiver', '42']", {}]}], "20": ["1.1 Definitions", {}], "21": ["1.2 Other Definitions", {}], "22": ["1.3 Currency", {}], "23": ["1.4 Headings", {}], "24": ["1.5 Exhibits", {}], "25": ["1.6 Applicable Law", {}], "26": ["2.1 Term", {}], "27": ["2.2 Effect of Expiration on Purchase Orders", {}], "28": ["3.1 Supply of Product", {}], "29": ["3.2 Manufacturing Services", {}], "30": ["3.3 Supply of Materials and Customer Material", {}], "31": ["3.4 Production Capacity", {}], "32": ["3.5 Processing Changes", {}], "33": ["3.6 Monitoring of Facilities", {}], "34": ["3.7 Subcontracting", {}], "35": ["3.8 [* * *]", {}], "36": ["3.9 [* * *]", {}], "37": ["3.10 Territory Expansion", {}], "38": ["3.11 Supply to Customer Licensees", {}], "39": ["3.12 Alternative Supply", {}], "40": ["4.1 Short Term Rolling Forecasts", {}], "41": ["4.2 Long Term Forecasts", {}], "42": ["5.1 Release Testing", {}]}}